A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs EP 7041 (Primary)
  • Indications Thrombosis
  • Focus Adverse reactions; First in man
  • Sponsors eXIthera Pharmaceuticals
  • Most Recent Events

    • 15 Nov 2017 Results (n=8) assessing safety, tolerability, pharmacokinetics and pharmacodynamics presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 14 Nov 2017 According to a eXIthera Pharmaceuticals media release, 60 healthy volunteers are been enrolled in this study.
    • 14 Nov 2017 According to a eXIthera Pharmaceuticals media release, results of the study were presented at the American Heart Association (AHA) Scientific Sessions in Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top